Kangsa Amporndanai

Jul 23, 2024 | pubs.acs.org | Ashley Taylor |Bin Zhao |Kangsa Amporndanai |Tyson A. Rietz

The Covid-19 pandemic caused by SARS-CoV-2, the present and future variants of this virus, and the potential for other coronaviruses to cause outbreaks highlight the need for antiviral drugs targeting critical proteins in the coronavirus life cycle. Currently, there are three FDA approved drugs for the treatment of Covid-19: two viral RNA dependent RNA polymerase inhibitors (Remdesivir and Molnupiravir) (1,2) and one viral main protease (Mpro) inhibitor (Nirmatrelvir).